Q-omics provides the consensus-scored TCF21 profile across patient tissues and cancer cell-line models. TCF21 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, TCF21 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TCF21 RNA expression shows 17,941 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, KIRC, and LSCC as cancer lineages where TCF21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCF21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCF21 survival associations across molecular data types. TCF21 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCF21 RNA expression–survival associations across cancer types. High TCF21 expression shows unfavorable associations in LUSC and KIRP, but favorable associations in LIHC, KIRC, LUAD and CHOL. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for TCF21 RNA expression.
This table summarizes TCF21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TCF21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCF21 shows lower tumor expression in KIRC, KICH, KIRP, BLCA, LUAD and COAD. The KIRC box plot shows higher TCF21 RNA expression in normal versus tumor tissue (log2 FC = −3.643, t-test p < 0.001).
This table shows molecular features associated with TCF21 in patient tissues and cancer cell lines. In patient samples, TCF21 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TCF21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
